Search
Cartesian Therapeutics Inc
RNACAdd to Watchlist
8.860USD
+0.020+0.23%
Market hours （ET）Quotes delayed by 15 min
230.39MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Cartesian Therapeutics Inc is 8.75, ranking 63 out of 387 in the Biotechnology & Medical Research industry. The average price target is 39.00, with a high of 44.00 and a low of 16.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
34.571
Target Price
+291.08%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Cartesian Therapeutics Inc
RNAC
8
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Cartesian Therapeutics Inc's expected revenue for the next quarter?
Cartesian Therapeutics Inc's expected revenue is 125.00K.
What is Cartesian Therapeutics Inc's price target?
Analysts forecast that Cartesian Therapeutics Inc's price target is USD 39.00, with the highest forecast at USD 44.00 and the lowest forecast at USD 16.00.
How have Cartesian Therapeutics IncRNAC's recent earnings per share performed?
The market expectation was USD 0.47, while Cartesian Therapeutics IncRNAC's earnings per share (EPS) for the previous quarter was USD -1.46. EPS for the next quarter is expected at USD -0.93.
What is the analyst rating for Cartesian Therapeutics Inc?
Based on the ratings of Cartesian Therapeutics Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.